ID   TTA-1
AC   CVCL_6297
SY   TTA1; TTA-I
DR   BTO; BTO:0004965
DR   cancercelllines; CVCL_6297
DR   CCRID; 3101HUMSCSP554
DR   CGH-DB; 46-1
DR   CLS; 305138
DR   Cosmic; 1152125
DR   Cosmic; 1239984
DR   Cosmic; 2054119
DR   RCB; RCB5467
DR   Wikidata; Q54973227
RX   Patent=US8029793;
RX   PubMed=8121182;
RX   PubMed=8176927;
RX   PubMed=9177455;
RX   PubMed=15613457;
RX   PubMed=16924234;
RX   PubMed=18713817;
RX   PubMed=23833040;
RX   PubMed=30737244;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7523.
CC   Population: Japanese.
CC   Doubling time: 28.8 hours (PubMed=8121182).
CC   Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Gly289fs (c.866delG); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 9,10
ST   D18S51: 15
ST   D21S11: 30
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 11,12
ST   D8S1179: 13,15
ST   FGA: 23
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   Patent=US8029793;
RA   Yoshida A., Yanoma S., Hirose F.;
RT   "Methods for inhibiting cell proliferation.";
RL   Patent number US8029793, 04-Oct-2011.
//
RX   PubMed=8121182; DOI=10.1002/jso.2930550209;
RA   Yoshida A., Asaga T., Masuzawa C., Kawahara S., Yanoma S., Harada M.,
RA   Okamoto T.;
RT   "Production of cytokines by thyroid carcinoma cell lines.";
RL   J. Surg. Oncol. 55:104-107(1994).
//
RX   PubMed=8176927; DOI=10.1002/jso.2930550308;
RA   Yoshida A., Asaga T., Masuzawa C., Kawahara S.;
RT   "Alteration of tumorigenicity in undifferentiated thyroid carcinoma
RT   cells by introduction of normal chromosome 11.";
RL   J. Surg. Oncol. 55:170-174(1994).
//
RX   PubMed=9177455; DOI=10.1016/S0304-3835(97)04742-3;
RA   Satake S., Sugawara I., Watanabe M., Takami H.;
RT   "Lack of a point mutation of human DNA topoisomerase II in
RT   multidrug-resistant anaplastic thyroid carcinoma cell lines.";
RL   Cancer Lett. 116:33-39(1997).
//
RX   PubMed=15613457; DOI=10.1677/erc.1.00818;
RA   Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.,
RA   Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.;
RT   "Comprehensive gene expression profiling of anaplastic thyroid cancers
RT   with cDNA microarray of 25 344 genes.";
RL   Endocr. Relat. Cancer 11:843-854(2004).
//
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//